Perimeter Medical Imaging Ai Inc Stock Price, News & Analysis

Perimeter Medical Imaging AI, Inc. (OTC:PYNKF) reported its Q3 2021 financial results, showing a net loss of $3,880,172 compared to a net income of $800,030 in Q3 2020. Operating expenses rose to $3,748,590 from $2,201,256 in the previous year. The company received FDA approval for its investigational device exemption (IDE) for the Perimeter B-Series OCT with ImgAssist AI, enabling a pivotal clinical trial to assess the technology's impact on breast conservation surgery. As of September 30, cash and equivalents stood at $7,775,195.

Perimeter Medical Imaging AI (OTC:PYNKF) has announced FDA approval for a pivotal study evaluating its B-Series OCT imaging system equipped with ImgAssist AI. This multi-center trial will assess its effectiveness in improving positive margin rates for breast cancer patients compared to standard care, with over 300 participants expected across 8 sites. Led by Principal Investigator Dr. Alastair Thompson at Baylor College of Medicine, the study aims to reduce re-operation rates in breast conservation surgeries. This milestone follows the 'Breakthrough Device Designation' received earlier this year.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK, OTC:PYNKF) announced the outcomes of its annual shareholder meeting held on October 27, 2021. Shareholders approved all resolutions, including the re-election of nine directors and the reappointment of KPMG LLP as auditors. Additionally, the stock option plan was amended to increase common shares reserved for issuance. The company granted 1,949,663 stock options at $2.85 each. Perimeter continues to advance its imaging technologies for cancer surgery, including the FDA-cleared S-Series OCT and the ImgAssist AI project.

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) will participate in the LD Micro Main Event Investor Conference from October 12-14, 2021, in Los Angeles, CA. CEO Jeremy Sobotta will present on October 12 at 3:30 pm PT. Perimeter's S-Series Optical Coherence Tomography (OCT) is FDA-cleared and offers real-time tissue visualization, potentially improving patient outcomes. The company is also developing the B-Series OCT with ImgAssist AI, funded by a $7.4 million grant from CPRIT, aimed at reducing re-operation rates in breast cancer surgeries.

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) will present at the Lytham Partners Fall 2021 Investor Conference on October 5, 2021, at 12:30 p.m. ET. The conference aims to showcase Perimeter's advanced imaging technologies designed to enhance cancer surgery outcomes. A webcast of the presentation will be available on their website. Management will also conduct virtual one-on-one meetings during the event, running from October 5-7. Perimeter is known for its S-Series OCT and B-Series OCT with ImgAssist AI technology.

Perimeter Medical Imaging AI, a medical technology company, announced its participation in upcoming industry events focused on cancer surgery and advanced imaging tools. Key highlights include Dr. Anthony Lucci's presentation on Optical Coherence Tomography at Mayo Clinic on September 17, 2021, and a poster presentation at the College of American Pathologists Annual Meeting from September 25-28, 2021. The CEO emphasized the importance of showcasing the Perimeter S-Series OCT system, which provides real-time visualization of excised tissue. The company is also advancing its B-Series OCT with ImgAssist AI, backed by a $7.4 million grant.

Perimeter Medical Imaging AI reported its Q2 2021 financial results, highlighting a net loss of $3.24 million, a decrease from $4.66 million in Q2 2020. Operating expenses increased to $3.06 million from $2 million in the previous year. Key developments included the U.S. FDA granting Breakthrough Device Designation for its imaging systems, the achievement of a 0.94 AUC in its ImgAssist AI algorithm, and plans for a pivotal study aimed at reducing breast cancer re-operation rates.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) announced significant progress in expanding its commercial organization, led by Chief Commercial Officer Steve Sapot. The company has hired four experienced market development managers to promote its S-Series OCT medical imaging technology in the U.S. market. Perimeter's innovative imaging system, cleared by the U.S. FDA, aims to enhance cancer surgery outcomes and reduce healthcare costs. Additionally, the company is advancing its ImgAssist AI technology under the ATLAS AI project, supported by a US$7.4 million grant.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) has announced that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC) in the U.S. This DTC eligibility aims to increase liquidity and enhance the company's presence in U.S. capital markets. CEO Jeremy Sobotta highlighted the benefits for existing shareholders, including faster execution speeds and greater opportunities to attract new investors. The company's imaging technology, including S-Series and B-Series OCT systems, is designed to improve cancer surgery outcomes.